285) Patient-specific computational fluid dynam |
286) y, we propose a semi-automated method for patient-specific computational flow modell |
287) Critically, it requires patient data and additional auditing of pr |
288) In this analysis, patient-level data from 31 randomized clin |
289) 10, with an incidence rate of 4.09/10 000 patient days in 2009 and 5.9/10 000 patien |
290) 2010 were analyzed and benchmarked using patient days. |
291) ound differences in their perspectives on patient empowerment and attributions of co |
292) gest novel research approaches to improve patient empowerment and medical engagement |
293) d four broad subtypes of URVs: related to patient factors, to the illness, to the sy |
294) This paper investigates whether patient-level factors, in particular cost |
295) anti-inflammatory drugs prescribed to one patient for a short period. |
296) trained and a navigator assigned to each patient for at least 2 months. |
297) The results demonstrate that rapid patient-side immunomigration assays design |
298) ections induced by BRSV by means of rapid patient-side immunomigration assays used f |
299) detailed understanding of the individual patient including their developmental stat |
300) important in the care of a critically ill patient, including the common errors to av |
301) ile educational interventions to increase patient motivation to pursue living donor |
302) nt determinants of effectiveness, such as patient's motivation and goal-directed reh |
303) A patient of 42 years is followed in Physica |
304) stimulating laser therapy in HIV-infected patients of varying degrees of immunodefic |
305) The patient outcome was fatal despite multimod |
306) ethodology for the case-mix adjustment of patient-reported outcome measures (PROMs) |
307) The FDS score for "Patient's pain and condition" was the high |
308) Patient pain rate, scar aesthetics and pat |
309) fter breast cancer surgery by examining a patient population from a tertiary cancer |
310) and be aware of its peculiarities in this patient population. |
311) rventions are widely recommended for this patient population, but to date no studies |
312) ms, they also occur in the critically ill patient population, where their presentati |
313) In addition, each patient received intravenous piracetam and |
314) The patient received radiation therapy postope |
315) apse 29 ± 21.65 weeks), and only one patient remained completely under control |
316) The patient remained well without evidence of |
317) The patient remains asymptomatic 1 year later. |
|